anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The neuropeptide oxytocin (OT) is crucial in several conditions, such as lactation, parturition, mother-infant interaction, and psychosocial function. Moreover, OT may be involved in the regulation of eating behaviors.
METHODS: This review briefly summarizes data concerning the role of OT in eating behaviors. Appropriate keywords and medical subject headings were identified and searched for in PubMed/MEDLINE. References of original articles and reviews were screened, examined, and selected.
RESULTS: Hypothalamic OT-secreting neurons project to different cerebral areas controlling eating behaviors, such as the amygdala, area postrema, nucleus of the solitary tract, and dorsal motor nucleus of the vagus nerve. Intracerebral/ventricular OT administration decreases food intake and body weight in wild and genetically obese rats. OT may alter food intake and the quality of meals, especially carbohydrates and sweets, in humans.
DISCUSSION: OT may play a role in the pathophysiology of eating disorders with potential therapeutic perspectives. In obese patients and those with certain eating disorders, such as bulimia nervosa or binge/compulsive eating, OT may reduce appetite and caloric consumption. Conversely, OT administered to patients with anorexia nervosa may paradoxically stimulate appetite, possibly by lowering anxiety which usually complicates the management of these patients. Nevertheless, OT administration (e.g., intranasal route) is not always associated with clinical benefit, probably because intranasally administered OT fails to achieve therapeutic intracerebral levels of the hormone.
CONCLUSION: OT administration could play a therapeutic role in managing eating disorders and disordered eating. However, specific studies are needed to clarify this issue with regard to dose-finding and route and administration time.
For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.
Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
PURPOSE:To provide a food having vasodilating effect, useful for the cure of shoulder discomfort, and having high safety, by using a pigment component of adzuki-bean extracted from adzuki-bean as an essential component. CONSTITUTION:The pigment component of adzuki-bean extracted from adzuki- bean (e.g. DAINAGON, red adzuki-bean, YABUTSURU, etc.) is used as an essential component of the titled food. The pigment component of adzuki-bean can be prepared by crushing the seed of adzuki-bean to the final particle size of about 50-20 mesh, preferably 40-30 mesh, adding 5-20 times vol of water or a hydrated lower aliphatic alcohol, and leaving at rest at room temperature for 12-48hr, heating the whole mixture at about 60 deg.C for 1-2hr, filtering the product, concentrating the filtrate to about 1/2-1/5, and subjecting to the freeze- drying, etc. to obtain a reddish brown powder. It dilates the peripheral vessel, promotes the blood flow in the peripheral vessel and the peripheral muscle, eliminates the congestion of the muscles of the shoulder and neck causing the shoulder discomfort, and cures the shoulder discomfort. 20-1,000mg of the pigment component is administered daily in 2-3 divided doses.
The Jarisch-Herxheimer reaction is a self-limiting systemic reaction that has been reported after the initiation of doxycycline therapy in up to 30% of patients with early Lyme disease. The reaction begins one to two hours after initiation of therapy and disappears within 12 to 24 hours. It is characterized by fever, chills, myalgias, headache, exacerbation of cutaneous lesions, tachycardia, hyperventilation, vasodilation with flushing, and mild hypotension. The pathogenesis of the Jarisch-Herxheimer reaction is unknown, but thought to be due to the release of spirochetal heat-stable pyrogen. Advise the patient of this reaction before starting LYMEPAK. Administer fluids and antipyretics to alleviate symptoms and duration of the reaction if severe.
The COVID-19 pandemic that swept the world in 2019 radically changed not only the social sphere of life, subordinating everything around to its influence, but also the healthcare sector. It affected both its practical and scientific sides, globally changing the approach to medicine. Numerous studies around the globe are being conducted on the prevention and treatment of this infection. A significant amount of them study the role of vitamin D in the pathogenesis of the disease. Cholecalciferol (Vitamin D) is a fat-soluble vitamin that is involved in maintaining the serum calcium-phosphorus gradient. Vitamin D supplementation significantly reduces the risk of osteoporosis, and also affects the regulation of immune responses by modulating innate and adaptive immune responses. It has been shown to inhibit the proliferation of T cells, namely the subsequent transformation of Th1 cells to Th2 cells. This effect on cell proliferation and differentiation contributes to a significant decrease in the level of proinflammatory cytokines, thereby reducing the severity of immune-mediated damage. It was these mechanisms that formed the basis of the theory about the ability of vitamin D to prevent the severe course of coronavirus infection and even prevent it. At the moment, the effect of vitamin D on reducing COVID-19 morbidity is not fully confirmed.
The present invention relates to plaster for activating collaterals and a manufacture method for the plaster. The plaster is stuck externally and is used for curing tumefaction, pain, fracture and tendon breakage caused by rheumatism, lumbocrural pain, traumatic injury, etc. The plaster comprises medicine components and collateral activating powder blended with the medicine components when the medicine components are cooled to the temperature below 100 DEG C in a powdery mode, wherein the medicine components have the following formulation by weight: 1.2 to 1.8 portions of Chinese angelica, 0.3 to 0.6 portion of rhubarb, 0.3 to 0.6 portion of red peony root, 0.3 to 0.6 portion of curcuma root, 0.5 to 0.9 portion of chuanxiong rhizome, 0.5 to 0.9 portion of red sage root, 0.1 to 0.4 portion of prism tuber, 0.1 to 0.4 portion of zedoary, 0.1 to 0.4 portion of radix aconite and 0.1 to 0.4 portion of wild aconite. One weight portion of the collateral activating powder has the following formulation by weight: notopterygium root, pubescent angelica root, acanthopanax bark, ledebouriella root, spikenard, radix aconite and wild aconite. The weight portion proportion of the collateral activating powder to the medicine components is 1: 15 to 25. The manufacture method comprises the steps that the medicine components are soaked in oil, the medicine oil is refined, pills are removed, the paste is collected, the collateral activating powder is added to the paste, an obtained product is coated, and the plaster is formed. The effective rate of the plaster reaches 95%, the recovery rate reaches more than 90%, and the plaster has no toxic or side effect on human bodies by clinical application. The selected medicinal materials can be obtained easily, and the manufacture method is simple, so that the cost is low.
Methods for the purification of proteinaceous materials, such as recombinant glucocerebrosidase (GCS) expressed in an insect cell culture that had been previously infected with a baculovirus carrying GCS-encoding nucleic acid, are disclosed. According to one embodiment, the medium is first clarified by being passed through a hollowfiber cartridge, then bacteria is filtered out. The filtered media is then concentrated with a cation exchange column, followed by hydrophobic interaction chromatography (HIC) purification. In alternative embodiments, the eluate from the cation exchange column and/or the HIC column is passed through an anion exchange column for removal of residual DNA, lipids and endotoxins. The purification methods of the present invention are quicker, cheaper, and capable of handling greater quantities and greater starting purities of conditioned media than processes previously utilized. The various methods of the present invention are also capable of providing commercial quantities of purified GCS suitable for therapeutic uses. Purified forms of GCS are also disclosed.
Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
VONJO causes diarrhea in approximately 48% of patients compared to 15% of patients treated on the control arm. The median time to resolution in VONJO-treated patients was 2 weeks. The incidence of reported diarrhea decreased over time with 41% of patients reporting diarrhea in the first 8 weeks of treatment, 15% in Weeks 8 through 16, and 8% in Weeks 16 through 24. Diarrhea resulted in treatment interruption in 3% of VONJO-treated patients. None of the VONJO-treated patients reported diarrhea that resulted in treatment discontinuation. Serious diarrhea adverse reactions occurred in 2% of patients treated with VONJO compared to no such adverse reactions in patients in the control arm.

Control pre-existing diarrhea before starting VONJO treatment. Manage diarrhea with antidiarrheal medications, fluid replacement, and dose-modification. Treat diarrhea with anti-diarrheal medications promptly at the first onset of symptoms. Interrupt or reduce VONJO dose in patients with significant diarrhea despite optimal supportive care [see Dosage and Administration ( 2.5)] .
This is a single arm interventional study in which the interventional and control arms are the same participant (each participant becomes its own control since the sentinel node biopsy- interventional arm - results are to be compared to systematic lymphadenectomy results-control arm). Intervention is injection of 2-4 mL sterile charcoal to the infundibulopelvic ligament or mesovarium of the suspicious adnexal mass followed by collection of stained sentinel lymph nodes and lymph nodes by systematic lymphadenectomy.
FIELD: medicine, colloidal chemistry. SUBSTANCE: copolymer of polyhydroxyethylene-polyhydroxypropylene (proxanol) is dissolved in water and egg yolk phospholipids and a mixture of perfluorodecaline and perfluoro-para-methylcyclopyridine taken at ratio 1:3 were added to solution. Mixture is stirred in turbine mixer at 4000-8000 rev/min for 1-2 min. Obtained parental coarse dispersed emulsion is passed many times (10-12 times) through hydroextrusion device under pressure 60-300 MPa at 1-20 C. Obtained emulsion shows average particle size is 0.157 mcm and diameter 0.05-0.34 mcm. Fluoride ion content in emulsion is 2.3 x 10M. Emulsion is used as blood substituent. Fraction of particle in emulsion at size above 0.2 mcm is decreased. EFFECT: lowered toxicity of emulsion. 1 tbl
Recent findings from a randomized control trial (RCT) show immediate between-group effects and evidence of target engagement on the hypothesized mechanism of action, memory for faces, which was evaluated by neuropsychological and event-related potential (ERP) measures. Moreover, the RCT demonstrated treatment effects on social communication skills that generalized to home and community settings. Finally, maintained treatment effects were observed on communication symptoms. The proposed project will extend these findings and provide a stronger test of efficacy using a multisite RCT of SENSE Theatre with a large sample of participants with ASD (8 to 16 years) randomized to an experimental and an active control group. The RCT will assess target engagement of memory for faces and functional change in social interaction with peers. Thus, the overarching aim of the study is to determine whether detected changes in face memory and social interaction are due to the SENSE Theatre treatment and the extent to which these changes generalize and maintain. If predicted results occur, it will provide strong empirical support for a community-based treatment that has generalized effects on a set of core deficits that otherwise have life-long consequences for children and adolescents with ASD.

8/18/2021: Record was updated to delete the outcome measure "Computer memory for faces" as it was not included as a primary outcome variable in the Institutional Review Board (IRB) approved protocol dated 9/13/2017.
Methods and systems are disclosed for component deconvolution by a mixture model based on methylation information. A mixture model may be trained agnostic of labels or known component contributions. A system generates a methylation signature for each of a plurality of training samples. The methylation signature may be based on a count or a percentage of a methylation variant(s) expressed in the methylation sequence reads of a training sample at each genomic region of a plurality of genomic regions. The system may train the mixture model using maximum likelihood estimation to deconvolve the component contributions. The mixture model may comprise component submodels and a deconvolution submodel. The component submodels predict a component likelihood based on the methylation signature. The deconvolution submodel predicts the component contributions based on the component likelihoods.
<P>PROBLEM TO BE SOLVED: To provide a humanized antibody specifically reacting with a prostate-specific membrane antigen (PSMA) having a new V region amino acid sequence and its antibody fragment, a fusion antibody thereof and a diagnostic agent and a therapeutic agent for cancer using the humanized antibody, the antibody fragment or the fusion antibody.  <P>SOLUTION: The humanized chimeric antibody specifically reacts with the PSMA and comprises an H chain composed of an H-chain V-region containing a specific amino acid sequence and an H-chain C-region of a human antibody and an L chain composed of an L-chain V-region containing a specific amino acid sequence and an L-chain C-region of the human antibody. Furthermore, the antibody fragment thereof and the fusion antibody of the chimeric antibody to interleukin 2 or an anticancer agent adriamycin are provided. The diagnostic agent for cancer comprises the chimeric antibody or its antibody fragment. Furthermore, the therapeutic agent for the cancer comprises the antibody, the antibody fragment or the fusion antibody.  <P>COPYRIGHT: (C)2004,JPO
Applicants have disclosed a wireless method for remotely monitoring the physiological status of ambulatory patients by using at least one "cloud" server. Physiological data, including ECG data, is collected by a device worn by a patient and then wirelessly transmitted (e.g., via a cell phone) to the server(s). The same device can alert a patient as to trouble, whereas the server can do the same to clinicians. Remote processing of electrocardiograms ("ECG") is achieved, in part, by data streaming packet lengths acquired over no less than 3 seconds - 3 seconds is typically equivalent to about 3 cardiac cycles (heartbeats) - to provide the quickest response time by clinicians to try to save a heart patient's life. Other physiological data (e.g., blood pressure, respiration, oxygen saturation) are monitored by the device, so medical help can be obtained when needed. In this manner, any sudden onset of vicissitudes in a patient's well being may be detected using physiological information from a parallel combination of vital signs, and transmitted to the care-giver and patient in a near real-time fashion.
Supine Hypertension: The most potentially serious adverse reaction associated with ProAmatine® therapy is marked elevation of supine arterial blood pressure (supine hypertension). Systolic pressure of about 200 mmHg were seen overall in about 13.4% of patients given 10 mg of ProAmatine®. Systolic elevations of this degree were most likely to be observed in patients with relatively elevated pre-treatment systolic blood pressures (mean 170 mmHg). There is no experience in patients with initial supine systolic pressure above 180 mmHg, as those patients were excluded from the clinical trials. Use of ProAmatine® in such patients is not recommended. Sitting blood pressures were also elevated by ProAmatine® therapy. It is essential to monitor supine and sitting blood pressures in patients maintained on ProAmatine®.
Improved coated medicaments and apparatus and methods of making the same are disclosed. Most preferably, products are coated at each end with gelatin or other coatings. The present invention discloses products having unequal coatings, as well as coatings applied to each end of a product which may or may not overlap, or leave, a portion of the product uncoated. The apparatus disclosed  comprises a hopper for retaining a plurality of the product in a predetermined orientation, and a feeder which fills a plurality of plate means retaining a plurality of the product. The product is most preferably retained in a pair of axially aligned specimens within a collet. The plates are incrementally advanced to a first dipping means and coated with a first coating material. After dipping, at least one of the plates is preferably rotated one and one-half times. A second rotating means places the plate back in its initial orientation, preferably, after one and one-half revolutions. The plates are then tranferred by second coatings. After extraction from the dyer, coated product is ejected from the plates. Methods of coating medicaments are also disclosed.
An ester-terminated dimer acid-based polyamide may be blended with a solvent to form a gel. The solvent may be flammable, and a wick may be added to the resulting gel so as to form a candle. Depending on the composition, the candle may be formed into a free standing pillar, or may be better suited to being placed in a container. The solvent may be mineral oil. A solid coating may be placed around the candle, for advantages including to enhance the clarity and/or mechanical stability of the gelled body, and to eliminate the tendency of a gel to have an oily feel and to accept noticeable fingerprints. The ester-terminated dimer acid-based polyamide may also be combined with an active ingredient, such as a fragrance, colorant, insect-repellant, insecticide, bioactive ingredient or the like, to afford a delivery vehicle for the active ingredient.
The present invention discloses a kind of preparation method containing sea grass polysaccharide skin film bath foam.(1) Entermorpha is cleaned, dry; Pulverize, cross 100 mesh sieves; (2) add the distilled water counting 20mL/g with the quality of Entermorpha, 90 DEG C of reflux, extract, 2 hours, filter, be separated residue and extracting solution.(3) residue repeats the step 2 time of (2).(4) said extracted liquid is merged, concentrated, obtain sea grass polysaccharide powder after lyophilization.(5) weight portion is respectively: the raw material of olive oil 1-5, glycerol 1-5 and rosemary ethereal oil 1-5 is mixed to get mixed liquor.(6) be that the distilled water of 70-90 is warming up to 70-90 DEG C by weight portion, add the sea grass polysaccharide powder that weight portion is 1-10, drip mixed liquor, with Fructus Citri Limoniae acid for adjusting pH to 5.5-6.5, concentrated.Gained bath foam of the present invention has antibacterial, nutrition protection skin, supplementary skin moisture; The metabolic balance of regulation of skin cell, makes skin gloss fine and smooth and high resilience; And help the multi-efficiencies such as fat-reducing and ultraviolet rays resistance.
We completed a retrospective review of data collected by the JH-CROWN consortium based on ICD10 codes for a hospitalized cohort. The severity and prevalence of COVID-19 and development of PASC within heritable connective tissue diseases were unknown; however, clinical observation suggested a thorough examination was necessary. We compared rates of disease severity, death, and PASC in connective tissue diseases versus the entire cohort as well as in diabetes and hypertension to determine if connective tissue disease was a risk factor. Of the 15,676 patients in the database, 63 (0.40%) had a connective tissue disease, which is elevated relative to the distribution in the population, suggesting a higher risk of severe disease. Within these 63 patients, 9.52% developed PASC compared to 2.54% in the entire cohort (p < 0.005). Elucidation of populations at high risk for severe disease and development of PASC is integral to improving treatment approaches. Further, no other study to date has examined the risk in those with connective tissue diseases and these data support a need for enhanced awareness among physicians, patients, and the community.
FIELD: medicine, preparative biochemistry. SUBSTANCE: invention relates to method of preparing gamma- globulin solution free of contaminating viruses designated for intravenous administration. Method involves stages of heat treatment at temperature from 50 C to 70 C for 10-100 h for inactivation of virus in the presence of stabilizing agent and fractionation of crude gamma-globulin solution with polyethylene glycol, treatment of gamma-globulin by ion-exchange resin followed by treatment of purified gamma-globulin with solvent-detergent for the further inactivation of viruses. Invention provides the development of combined multistage commercial process for preparing gamma-globulin that involves removal of denatured protein formed in heat sterilization. EFFECT: improved method of preparing, enhanced purity of preparation. 8 cl, 2 ex
HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.